Filing Flows › Entrada Therapeutics (TRDA) › Q2 2025
Entrada Therapeutics (TRDA) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Entrada Therapeutics (TRDA) reported revenue of $1.9M for the second quarter 2025 (Q2 2025), -98% from a year earlier and -91% from the quarter before.
Entrada Therapeutics, Q2 2025: revenue $1.9M (-98% year over year), net loss $43.1M, operating cash flow −$29.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.9M | -91% | -98% |
| Operating profit | −$46.8M | — | — |
| Net earnings | −$43.1M | — | — |
| Operating cash flow | −$29.5M | — | — |
What changed
Revenue was $1.9M in Q2 2025, down 98% year over year and down 91% from the previous quarter.
Operating costs exceeded revenue by $46.8M, an operating margin of -2402.5%. Total costs grew 18% against a revenue fall of 98%. The fastest-growing cost line was General & admin (+18%). The quarter ended with a net loss of $43.1M, wider than the previous quarter's $17.3M loss.
Operating cash flow was −$29.5M. Non-cash charges added back $1.1M of depreciation and $5.0M of share-based compensation. Working capital and other items added $7.5M. Capital expenditures of $275K exceeded it, leaving free cash flow of −$29.8M.
Questions
What was Entrada Therapeutics' revenue in the second quarter 2025?
Entrada Therapeutics (TRDA) reported revenue of $1.9M for the second quarter 2025 (Q2 2025), -98% from a year earlier and -91% from the quarter before.